The single most important number on an androgen protocol
Testosterone stimulates red-blood-cell production, so hematocrit rises on a protocol — predictably, dose-dependently, and silently. There is no symptom that tells you your blood is getting too thick. That combination — a marker that climbs without warning and, when high enough, raises blood viscosity and thrombotic risk — is what makes hematocrit the hard safety line of enhancement. Every other expected shift is a dial; this one is a line.
The thresholds, attributed honestly
Be precise about where the numbers come from, because a safety course shouldn't dress clinical convention up as guideline law:
- The major endocrine guideline defines testosterone-induced erythrocytosis at a hematocrit above ~54%, and the recommendation is to withhold therapy until it normalizes, then resume at a lower dose. This is the firmest, guideline-stated line.
- Many clinicians begin watching closely around 52% — sound practice, but a convention rather than a named guideline cutoff.
- Some guidance also treats a baseline hematocrit above ~48–50% as a reason not to start therapy until it's addressed.
So: ~54% is the action line you can cite; ~52% is the "pay attention" zone; and a high baseline is a flag before you even begin.
The hydration trap
Before you act on a high reading, confirm it on a hydrated draw. Hematocrit is the most hydration-sensitive marker on the panel — a dehydrated draw can inflate it by several points, and people have run unnecessary phlebotomy chasing a number that was really just a dry blood draw. A genuinely high hematocrit repeats on a properly hydrated re-test; an artifact resolves.
Managing a genuinely high hematocrit
When the value is real and crossing the line, the levers are: reduce the dose (the root cause), improve injection frequency (large infrequent doses produce bigger peaks and more erythrocytosis than smaller frequent ones), address sleep apnea if present (a major independent driver), and ensure hydration. Therapeutic phlebotomy or blood donation is used to bring an elevated hematocrit down, but with two caveats: it is treating the symptom, not the cause, and frequent phlebotomy drives iron stores and ferritin down, sometimes into symptomatic deficiency — so the fix for one problem can manufacture another if you're not tracking ferritin alongside hematocrit.
A note on the evidence, and on not panicking
The honest nuance: the evidence base for exactly when secondary erythrocytosis from testosterone causes harm is less ironclad than the threshold suggests, and some researchers argue the thrombotic risk in an otherwise-healthy man at 52–54% is lower than long assumed. That is not license to ignore it — it is a reason to treat the line seriously and to act with judgment rather than panic: confirm on a hydrated draw, look at the whole cardiovascular picture (blood pressure, lipids), and manage the dose rather than reflexively bleeding yourself. The discipline is to respect the hard line without treating every reading as an emergency.
The throughline
Hematocrit is the marker that the rationalization "but my testosterone is dialed in" exists to defeat. It is silent, it is the firmest safety line in enhancement, and it is read on a hydrated draw, managed at the dose, and tracked alongside ferritin. No good number anywhere else buys it back.
Educational content, not individual medical advice.